Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
4.48 USD
444.09 M USD
1.02 B USD
115.68 M
About Halozyme Therapeutics, Inc.
Sector
Industry
CEO
Helen I. Torley
Website
Headquarters
San Diego
Founded
1998
ISIN
US40637H1095
FIGI
BBG000CZ8W54
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
Related stocks
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
HALO5638653
Halozyme Therapeutics, Inc. 1.0% 15-AUG-2028Yield to maturity
—
Maturity date
Aug 15, 2028
HALO5387960
Halozyme Therapeutics, Inc. 0.25% 01-MAR-2027Yield to maturity
—
Maturity date
Mar 1, 2027
See all HALO bonds
Curated watchlists where HALO is featured.
Frequently Asked Questions
The current price of HALO is 77.81 USD — it has increased by 1.47% in the past 24 hours. Watch Halozyme Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Halozyme Therapeutics, Inc. stocks are traded under the ticker HALO.
HALO stock has risen by 1.00% compared to the previous week, the month change is a 11.64% rise, over the last year Halozyme Therapeutics, Inc. has showed a 24.54% increase.
We've gathered analysts' opinions on Halozyme Therapeutics, Inc. future price: according to them, HALO price has a max estimate of 91.00 USD and a min estimate of 51.00 USD. Watch HALO chart and read a more detailed Halozyme Therapeutics, Inc. stock forecast: see what analysts think of Halozyme Therapeutics, Inc. and suggest that you do with its stocks.
HALO reached its all-time high on Sep 19, 2025 with the price of 77.95 USD, and its all-time low was 1.41 USD and was reached on Aug 17, 2004. View more price dynamics on HALO chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
HALO stock is 2.34% volatile and has beta coefficient of 0.09. Track Halozyme Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Halozyme Therapeutics, Inc. there?
Today Halozyme Therapeutics, Inc. has the market capitalization of 9.10 B, it has decreased by −2.22% over the last week.
Yes, you can track Halozyme Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Halozyme Therapeutics, Inc. is going to release the next earnings report on Nov 10, 2025. Keep track of upcoming events with our Earnings Calendar.
HALO earnings for the last quarter are 1.54 USD per share, whereas the estimation was 1.24 USD resulting in a 23.77% surprise. The estimated earnings for the next quarter are 1.63 USD per share. See more details about Halozyme Therapeutics, Inc. earnings.
Halozyme Therapeutics, Inc. revenue for the last quarter amounts to 325.72 M USD, despite the estimated figure of 285.91 M USD. In the next quarter, revenue is expected to reach 339.73 M USD.
HALO net income for the last quarter is 165.16 M USD, while the quarter before that showed 118.09 M USD of net income which accounts for 39.85% change. Track more Halozyme Therapeutics, Inc. financial stats to get the full picture.
No, HALO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 21, 2025, the company has 350 employees. See our rating of the largest employees — is Halozyme Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Halozyme Therapeutics, Inc. EBITDA is 764.36 M USD, and current EBITDA margin is 62.32%. See more stats in Halozyme Therapeutics, Inc. financial statements.
Like other stocks, HALO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Halozyme Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Halozyme Therapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Halozyme Therapeutics, Inc. stock shows the strong buy signal. See more of Halozyme Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.